Streetbeat News

SGHT

Sight Sciences, Inc.

https://www.sightsciences.com

Industry

Medical - Devices

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Open

2.62

Mkt cap

140M

Volume

200K

High

2.73

P/E Ratio

-2.64

52-wk high

8.45

Low

2.56

Div yield

N/A

52-wk low

2.17

Sight Sciences has reduced its FY23 revenue guidance from $89M-$94M to $80M-$82M, which is significantly lower than the estimated $92.12M.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:12 pm

Morgan Stanley analyst Cecilia Furlong has downgraded Sight Sciences (NASDAQ:SGHT) from Overweight to Equal-Weight and lowered the price target from $12 to $8.4.

Portfolio Pulse from richadhand@benzinga.com

August 24, 2023 | 9:16 am

Over the past 3 months, 6 analysts have published their opinion on Sight Sciences (NASDAQ:SGHT) stock. The company has an average price target of $10.17, a decrease of 25.6% from the previous average price target of $13.67. The ratings include 2 bullish, 1 somewhat bullish, and 3 indifferent.

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 12:01 pm

Citigroup analyst Joanne Wuensch has maintained a Neutral rating on Sight Sciences (NASDAQ:SGHT) and lowered the price target from $9 to $8.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 11:32 am

Morgan Stanley analyst Cecilia Furlong has maintained an Overweight rating on Sight Sciences (NASDAQ:SGHT) but lowered the price target from $15 to $12.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 7:23 pm

Sight Sciences (NASDAQ:SGHT) reported Q2 losses of $(0.30) per share, beating the analyst consensus estimate of $(0.34) by 11.76%. This is a 40% increase over losses from the same period last year. The company also reported quarterly sales of $23.47 million, beating the analyst consensus estimate of $22.40 million by 4.78%. This is a 36.23% increase over sales from the same period last year.

Portfolio Pulse from totan@benzinga.com

August 04, 2023 | 2:28 pm

Several stocks experienced significant movement in Friday's mid-day session. Notable gainers include Digital World Acquisition Corp. (DWAC), which jumped 69% after reaching a settlement with the SEC, and ServisFirst Bancshares, Inc. (SFBS), which rose 17.3% following positive Q2 results. On the other hand, Sigma Additive Solutions, Inc. (SASI) fell 34.6%, and Metropolitan Bank Holding Corp. (MCB) dipped 9.3% following weak quarterly results.

Portfolio Pulse from Lisa Levin

July 21, 2023 | 5:01 pm

Several US stocks traded higher on Friday, with notable gains for Digital World Acquisition Corp. (DWAC), Evelo Biosciences (EVLO), ServisFirst Bancshares (SFBS), Scholastic Corporation (SCHL), Matson (MATX), POSCO Holdings (PKX), Sight Sciences (SGHT), Autoliv (ALV), Stoke Therapeutics (STOK), Hyzon Motors (HYZN), Inter & Co (INTR), Sify Technologies (SIFY), United Homes Group (UHG), Forestar Group (FOR), Etsy (ETSY), WNS (Holdings) (WNS), and Zoetis (ZTS). Reasons for the gains include settlements with the SEC, termination of sublease agreements, upbeat Q2 results, stock repurchase programs, and analyst upgrades.

Portfolio Pulse from Lisa Levin

July 21, 2023 | 2:23 pm

Sight Sciences Inc (NASDAQ:SGHT) has released six-month trial data showing that its TearCare Technology, used in interventional eyelid procedures for dry eye disease, has surpassed Restasis in effectiveness. The trial met its primary endpoint, with statistically significant improvements compared to Restasis eye drops. The next phase of the study will see subjects in the Restasis cohort switch to TearCare, with final results expected by 2025. SGHT shares are up 0.91% at $7.78.

Portfolio Pulse from Vandana Singh

July 20, 2023 | 4:19 pm

Sight Sciences has announced that its Sahara clinical trial, which compared interventional eyelid procedures enabled by TearCare technology to Restasis for the treatment of dry eye, has met its primary endpoint. The company's stock symbol is SGHT.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 12:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.